Stellate Therapeutics is a pre-clinical stage start-up company developing innovative microbiome-derived small molecules to treat neurodegenerative diseases. We utilize the microbiome for our drug portfolio and our research focuses on the gut-brain axis. Due to millions of years of co-evolution, complex metabolic interactions exist between humans and their gut bacteria and Stellate has uncovered a unique set of metabolites that are produced by the microbiome and are involved in the maintenance of health. Our first drug will be a treatment for Parkinson’s disease.